Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 15 May 2017


ANTHRASIL is an Anthrax Immune Globulin Intravenous (Human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs (1).

The effectiveness of ANTHRASIL is based solely on efficacy studies conducted in animal models of inhalational anthrax.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more



Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

Load more

Related Content

Advisory information

• History of anaphylactic or severe systemic reaction to human immune globulins (4)
• IgA deficiency with antibodies against IgA and a history of IgA hypersensitivity (4)
Special warnings and precautions

See full prescribing information for complete boxed warning.
• Maltose in immune globulin products, including ANTHRASIL, may give falsely high blood glucose levels with some blood point-of-care glucose testing systems (for example those based on the GDH-PQQ or glucose-dye-oxidoreductase methods) resulting in inappropriate administration of insulin and life-threatening hypoglycemia. To avoid interference by maltose contained in ANTHRASIL, perform blood glucose measurements in patients receiving ANTHRASIL with a glucose-specific method (monitor and test strips).
• Thrombosis may occur with immune globulin products, including ANTHRASIL. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
• For patients at risk of thrombosis, administer ANTHRASIL at the minimum infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

• Hypersensitivity reactions including anaphylaxis (5.1)
• Interference with blood and urine glucose testing (5.2, 5.9)
• Thrombosis may occur. Monitor patients at risk (5.3)
• Monitor renal function and urine output in patients at risk of acute renal dysfunction/failure (5.4)
• Infuse ANTHRASIL at the minimum rate practicable in patients at risk of thrombosis or renal failure (5.5)
• Monitor for clinical signs and symptoms of hemolysis and hemolytic anemia (5.6)
• Aseptic meningitis syndrome (AMS) (5.7)
• Transfusion-related Acute Lung Injury (TRALI) (5.10)
• Transmission of infectious agents from human plasma (5.11)

Adverse reactions

The most common adverse reactions to ANTHRASIL observed in >5% of healthy volunteers in clinical trials were headache, infusion site pain and swelling, nausea, and back pain (6.1).

Usage information

Dosing and administration
For intravenous use only.

Patient Group Dosea Starting Infusion Rate (first 30 min) Incremental Infusion Rate if Tolerated (every 30 min) Max Infusion Rate
Adults (≥17 years) 7 vials
(420 units)
0.5 mL/min 1 mL/min 2 mL/min
Pediatric <1 year to ≤16 years 1–7 vials (60–420 units) based on patient weight 0.01 mL/kg/min (do not exceed the adult rate) 0.02 mL/kg/min 0.04 mL/kg/min (do not exceed the adult rate)

aSelect initial dose based on clinical severity; severe cases may warrant use of 14 vials (840 units) in adults and 2 to 14 vials (based on weight) in pediatric patients weighing >5 kg.

Adjust dose and consider redosing based on clinical severity and response to treatment (2.1)

Weight-based Pediatric Dose
Body Weight (kg) Vials per Dosea Body Weight (kg) Vials per Dose
<5 1 25 to <35 4
<10 1 35 to <50 5
10 to <18 2 50 to <60 6
18 to <25 3 ≥60 7

aSelect initial dose based on clinical severity. Dose may be doubled for severe cases in patients >5 kg.

Administer ANTHRASIL by slow intravenous infusion using an infusion pump (maximum 2 mL per minute).

Use in special populations
• Pregnancy: No human or animal data are available (8.1)

More information

Category Value
Authorisation number BLA125562
Orphan designation No
Product NDC 60492-0249
Date First Approved 05-10-2015
Marketing authorisation holder Cangene Corporation